Fungal infection in patients with end-stage liver disease: low frequency or low index of suspicion  by Hassan, Elham A. et al.
International Journal of Infectious Diseases 23 (2014) 69–74Fungal infection in patients with end-stage liver disease:
low frequency or low index of suspicion
Elham A. Hassan a,*, Abeer S. Abd El-Rehim a, Sahar M. Hassany a, Asmaa O. Ahmed b,
Nahla M. Elsherbiny c, Mona H. Mohammed c
aDepartment of Tropical Medicine and Gastroenterology, 6th Floor, Faculty of Medicine, Assiut University, 71111, Assiut, Egypt
bDepartment of Clinical Pathology, Faculty of Medicine, Assiut University, Assiut, Egypt
cDepartment of Medical Microbiology and Immunology, Faculty of Medicine, Assiut University, Assiut, Egypt
A R T I C L E I N F O
Article history:
Received 17 October 2013
Received in revised form 15 November 2013
Accepted 12 December 2013
Corresponding Editor: Eskild Petersen,
Aarhus, Denmark
Keywords:
Fungal infection
Serum IL-17
End-stage liver disease
Spontaneous fungal peritonitis
Fungemia
S U M M A R Y
Background: End-stage liver disease (ESLD) is associated with dysregulation of the immune system and
increased susceptibility to infections. Although invasive fungal infection (IFI) is a growing public health
problem, studies of IFI in ESLD are lacking. The aims of this study were to screen for IFI in ESLD and to
assess risk factors and serum interleukin 17 (IL-17) as a marker of the cellular immune response.
Methods: Both blood and ascitic ﬂuid samples were collected from 46 patients with ESLD for fungal
culture and PCR. Serum IL-17 levels were determined.
Results: Seven patients had isolated IFI (four had spontaneous fungal peritonitis, two had fungemia, and
one had a disseminated fungal infection) and ﬁve cases had combined fungal and bacterial infections.
Spontaneous fungal peritonitis was attributed to Candida species, while fungemia was caused by
Aspergillus species. Patients with IFI had higher serum IL-17 levels and increased mortality compared to
patients without IFI. A history of antibiotic use (p = 0.002), higher model for end-stage liver disease
(MELD) scores (p = 0.04), and hepatorenal syndrome (p = 0.006) were risk factors for IFI.
Conclusions: Patients with ESLD had a low frequency of IFI; however, in patients with these infections,
delayed diagnosis and treatment may contribute to a high fatality rate. Thus, clinicians should have a
high index of suspicion for this unusual but lethal entity, as prompt detection and appropriate treatment
can improve the outcome.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious
Diseases. 
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Invasive fungal infection (IFI) is a serious infection that has a
detrimental effect in patients with serious diseases or who are in
an immune deﬁcient state. The diagnosis of IFI requires
histopathological evidence of tissue invasion, or isolation in blood
cultures, or isolation from a normally sterile body ﬂuid or site, with
samples collected intraoperatively or by percutaneous needle
aspiration.1,2 Awareness of IFI has increased in clinical practice
with the increased survival of patients in immunocompromised
states.3 Such infections are associated with a high morbidity and       
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http://dx.doi.org/10.1016/j.ijid.2013.12.014signiﬁcant mortality, requiring early diagnosis and appropriate
treatment, but also optimal prophylaxis in patients at high risk.4
End-stage liver disease (ESLD) refers to advanced liver disease
with hepatic ﬁbrosis and complications, including portal hyper-
tension, ascites, encephalopathy, synthetic dysfunction, and
impaired metabolic capacity.5 In addition, ESLD is associated with
defects in host immunity and co-morbid diseases, e.g. diabetes
mellitus, renal impairment, and malignancy. Thus, these patients
are highly susceptible to different types of infection. However, to
our knowledge, studies on IFI in ESLD patients are lacking,
especially from our region.
IFI in ESLD raises important questions. First, how frequent is
this infection; is the frequency low or underestimated? Second,
what are the methods for rapid and early diagnosis of fungal
infection? Third, are there any differences between fungal and
other infections regarding risk factors and clinical judgment?
Fourth, what is the relative contribution of the host immune
response to this infection? We sought to answer these questions.
Hence the aims of this study were to screen for IFI in ESLD, identifyociety for Infectious Diseases. Open access under CC BY-NC-ND license.
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infections through interleukin 17 (IL-17).
2. Patients and methods
2.1. Study design
This was a prospective study carried out at Assiut University
Hospital (AUH), Egypt, from January to August 2013. The study was
approved by the ethics committee of AUH. Patients (or relatives of
comatose patients) provided informed consent for study participa-
tion. The aim of the present study was to demonstrate the frequency
of IFI in ESLD, risk factors, and cellular immunity against it.
2.2. Patients
Forty-six patients with ESLD were selected from the intensive
care unit (ICU) of the Tropical Medicine and Gastroenterology
Department, AUH. All patients met the diagnostic criteria for liver
cirrhosis by clinical, biochemical, and ultrasonography ﬁndings. The
severity of liver cirrhosis was assessed according to the Child–Pugh
classiﬁcation and model for end-stage liver disease (MELD) score.6,7
Cirrhotic patients with a history of intra-abdominal surgery were
not included in the study to exclude secondary peritonitis.
At study entry, a thorough medical history was taken and
physical examination performed, and blood and ascitic ﬂuid
samples were collected. In-hospital mortality was assessed.
2.3. Specimen collection and processing
For each patient, 15–20 ml of blood and ascitic ﬂuid were
collected aseptically. Three milliliters of the blood sample were
used for serum separation and stored at 20 8C (for assessment of
IL-17, serology for HIV and cytomegalovirus (CMV), and also for
DNA extraction). The remaining sample was used for biochemical
examination, complete blood picture, and microbiological culture.
Two milliliters of the ascitic ﬂuid sample were stored at 20 8C (for
DNA extraction for the detection of universal fungal gene), while
the remaining sample was used for smears, bacterial and fungal
cultures, and biochemical examination.
2.4. Specimen examination
Liver function, kidney function, blood picture (total and
differential white blood cell count), and serum glucose and
sodium were determined using the blood samples. The total
leukocyte count, cell types, total protein content, and cytology
were assessed in the ascitic ﬂuid samples.
Assessment of the IL-17 level in serum was done by ELISA
(Quantikine ELISA, Human IL-17; R&D Systems) as per the
manufacturer’s instructions.
HIV serology was determined by simultaneous qualitative
detection of HIV p24 antigen and antibodies to HIV type 1 and/or
type 2 (Abbott ARCHITECT HIV Ag/Ab Combo Assay). In addition,
CMV antibodies were detected using the Abbott ARCHITECT CMV
IgM and IgG assays in accordance with the manufacturer’s
instructions.
Smears were made from centrifuged ascitic ﬂuid samples and
were stained with Gram stain, Ziehl–Neelsen stain, and India ink
stain (for the detection of Cryptococcus neoformans capsules if
present).
For cultures, each ascitic ﬂuid and blood sample was inoculated in
an aerobic blood culture bottle (for detection of aerobic bacteria), in
two bottles of Sabouraud’s dextrose broth (for fungal detection), and
on Lowenstein–Jensen (LJ) slants (for Mycobacterium detection).
Aerobic blood culture bottles were incubated at 37 8C, whileSabouraud’s dextrose broth bottles were incubated at 25 8C and
37 8C, respectively, for up to 14 days, or until positive growth was
detected. Candida colonies on Sabouraud’s dextrose agar were
identiﬁed by Gram stain, germ tube test, and culture on CHROMagar
Candida medium (CHROMagar, Paris, France) and corn meal agar.
Filamentous fungi on Sabouraud’s dextrose agar were identiﬁed
macroscopically and microscopically by examining the shape and
arrangement of the conidia using lactophenol cotton blue stain.8 For
bacterial cultures, subcultures were done on blood agar and
MacConkey agar. The LJ slants were incubated at 37 8C for 4–8
weeks and observed weekly.
2.5. DNA extraction from serum and ascitic samples
For serum samples, DNA was extracted using the QIAamp DNA
Blood Mini Kit (Qiagen, Germany), while for ascitic ﬂuid samples,
DNA was extracted using the MasterPure Complete DNA Puriﬁca-
tion Kit (Epicenter Biotechnologies, Madison, WI, USA), both in
accordance with the manufacturer’s instructions.
2.6. Primers for fungal detection
Universal fungal primers for 28S rDNA were used. They were as
follows:
22-bp forward primer, CTSF (50-TCG CAT CGA TGA AGA ACG
CAG C-30), and 25-bp reverse primer, CTSR (50-TCT TTT CCT CCG
CTT ATT GAT ATG C-30).
2.7. DNA ampliﬁcation and detection
A conventional PCR for the ampliﬁcation of target DNA was
carried out using PCR Beads in a total volume of 25 ml containing
5 ml of DNA template, 1 ml of each primer, and 18 ml of distilled
water. PCR cycling was carried out in the thermal cycler (HYBAID-
PCR Express) and was programmed for the following PCR steps:
after 3 min of initial denaturation at 94 8C, the reaction mixture
was run through 35 cycles of denaturation for 1 min at 94 8C,
annealing for 30 s at 60 8C, and extension for 1 min at 72 8C. This
was followed by a ﬁnal extension for 10 min at 72 8C.9
Finally, 10 ml of PCR product was mixed with 4 ml of 6 loading
buffer and electrophoresed on a 2% agarose gel for 20 min at 130 V,
using 1 Tris-borate-EDTA (TBE) buffer. The gel was stained with
ethidium bromide (0.2 mg/l). After electrophoresis, amplicons
were made visible by UV light. The size of the ampliﬁed DNA
fragment (550 bp) was identiﬁed by comparison with molecular
size marker DNA (100-bp DNA ladder).
2.8. Statistical analysis
The statistical analysis was performed using SPSS version 17.0
for Windows (SPSS Inc., Chicago, IL, USA). Continuous data were
expressed as the mean  standard deviation (SD) and compared
using the Student’s t-test. Categorical variables were expressed as the
percentage and compared using the Chi-square test of Fisher’s exact
probability test. Multiple regression analysis was used to study the
inﬂuence of independent variables on fungal infection. The level of
signiﬁcance was set at p < 0.05.
3. Results
3.1. Distribution of infections in the study patients
Forty-six patients with ESLD (28 males and 18 females) aged
45–72 years (mean age 56.7  6.4 years) were included in this study.
By microbial analysis of the ascitic ﬂuid and blood samples of these
patients with ESLD, 28 cases of infection were identiﬁed: 10 females
Table 2
Different settings and methods of detection of invasive fungal infection (IFI).
IFI
(isolated)
IFI plus
bacterial/
TB infection
IFI total
Conventional culture 1/7 (14.3%) 0 1/12 (8.3%)
PCR 2/7 (28.6%) 1/5 (20%) 3/12 (25%)
Conventional culture
and PCR
4/7 (57.1%) 4/5 (80%) 8/12 (66.7%)
Total 7 5 12
% 7/46 (15%) 5/46 (10.8%) 12/46 (26%)
TB, tuberculosis.
Table 1
Frequency of infection in the study patients with end-stage liver
disease (in ascitic ﬂuid and/or blood).
Infection Frequency
No infection 18 (39.1%)
Isolated bacterial infection 11 (21.7%)
Isolated TB infection 4 (8.7%)
Isolated fungal infection 7 (15.2%)
Combined infection
TB and fungal
TB and bacteria
Fungal and bacterial
6 (13%)
3
1
2
Total 46 (100%)
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(eight females and 10 males) had no infection, and their mean age was
54.3  6.8 years. The distribution of infections in the study patients is
illustrated in Table 1.
3.2. Diagnosis of fungal infection
Mycological culture assay indicated the growth of fungal
species in ﬁve ascitic ﬂuid samples and seven blood samples. TheseTable 3
Details of risk factors and associated microbial infections among patients with end-sta
Case Sex Age,
years
Host
factors
C–P MELD AF poly
(>250
cells/mm3)
1 M 60 HE, recurrent SBP, HRS, antibiotic
therapy, HCC
14 33 No 
2 F 60 HE, DM, HCC, recurrent SBP, HRS,
antibiotic therapy
11 20 No 
3 F 45 DM, intractable ascites, antibiotic
therapy, HE
11 21 No 
4 M 72 HE, DM, HRS, hematemesis, recurrent
SBP, antibiotic therapy
13 25 No 
5 M 55 HE, recurrent SBP, HCC, HRS, antibiotic
therapy
14 40 No 
6 M 50 HE, recurrent SBP, HCC, intractable
ascites, antibiotic therapy, HRS
13 33 No 
7 M 58 HE, hematemesis, HRS, antibiotic
therapy
14 41 Yes 
8 M 69 HE, hematemesis, DM, HRS, antibiotic
therapy
12 22 No 
9 F 60 DM, intractable ascites, HE chest
infection, recurrent SBP
11 24 No 
10 F 47 Recurrent SBP 11 30 Yes 
11 M 60 HE, DM, HCC, intractable ascites,
recurrent SBP, HRS
14 23 Yes 
12 M 55 DM, intractable ascites 13 30 No 
AF poly, ascitic ﬂuid polymorphs; C–P, Child–Pugh classiﬁcation; DM, diabetes mellit
hepatorenal syndrome; IL-17, interleukin 17; M, male; MELD, model for end-stage liv
methicillin-sensitive Staphylococcus aureus; Neg, negative; Pos, positive; SBP, spontane
a Aspergillus species: A. niger and A. ﬂavus. Candida species: C. albicans and C. tropspecies were Candida (four in blood and three in ascitic ﬂuid) and
Aspergillus (four in blood and two in ascitic ﬂuid). None of the
patients had a C. neoformans infection. By PCR, 13 samples (six
ascitic ﬂuid and seven blood) were positive for fungal DNA (Tables
2 and 3).
We found that 12 cases had a fungal infection (eight males and
four females) and their mean age was 57.6  8 years. Of these, seven
cases (15.2%) had an isolated fungal infection: two of them had
fungemia only (one by culture and one by culture and PCR), four had
spontaneous fungal peritonitis only (two by culture and PCR and two
by PCR), and one case had fungal isolation from ascitic ﬂuid (by
culture and PCR) as well as from blood (by culture and PCR) giving the
diagnosis of disseminated fungal infection. The ﬁve remaining cases
of fungal infection were combined with (or superimposed on)
bacterial infections (two cases) and tuberculosis (three cases) (Tables
2 and 3).
The demographic characteristics, host factors, and microbio-
logical data of these patients are shown in Table 3.
3.3. Comparison between fungal and non-fungal infections
The demographic, clinical, and laboratory characteristics and
underlying predisposing conditions of the study patients according
to their microbial assessment are shown in Table 4. There was no
signiﬁcant difference in age, gender, or clinical data between the
fungal infection group and the other groups. Regarding underlying
risk factors, a history of prophylactic antibiotics, MELD scores, and
hepatorenal syndrome were signiﬁcantly higher in patients with
fungal infections compared to those with bacterial infections and
those without infection. None of the patients had a history of
corticosteroid use or immunosuppressive therapy. With regard to
laboratory ﬁndings, patients with fungal infections had higher IL-
17 levels than those in the other groups, but this was not
statistically signiﬁcant. No patient had neutropenia (an absolute
neutrophil count <0.5  109/l). Also, none of patients had evidencege liver disease with fungal infection
Fungal infectiona Serum
IL-17 (pg/dl)
Other
organisms
Outcome
Culture PCR Ascites Blood
Ascites Blood Ascites Blood
Neg A. niger Neg Pos 24.1 Neg Neg Alive
Neg A. niger Neg Neg 28.6 Neg Neg Died
C. albicans C. albicans Pos Pos 26.9 Neg Neg Alive
C. albicans Neg Pos Neg 22.4 Neg Neg Alive
A. niger Neg Pos Neg 100 Neg Neg Alive
Neg Neg Pos Neg 22.7 Neg Neg Alive
Neg Neg Pos Neg 23 Neg Neg Died
Neg A. ﬂavus Neg Pos 27.8 MSSA Neg Alive
Neg C. albicans Neg Pos 30.1 TB Neg Alive
A. niger A. niger Pos Pos 23.5 TB Neg Alive
C. albicans C. albicans
C. tropicalis
Neg Pos 32.3 MRCNS Neg Alive
Neg Neg Neg Pos 30 Neg TB Alive
us; F, female; HCC, hepatocellular carcinoma; HE, hepatic encephalopathy; HRS,
er disease; MRCNS, methicillin-resistant coagulase-negative staphylococci; MSSA,
ous bacterial peritonitis; TB, tuberculosis.
icalis.
Table 4
Comparison of demographic, clinical, and laboratory characteristics and associated risks among the study patients according to their microbial assessmenta.
Isolated fungal
infection (n = 7)
Bacterial
infection
(n = 16)b
No infection
(n = 18)
p-Value, fungal vs.
bacterial infection
p-Value, fungal vs.
no infection
Age, years 57  8.6 58  5.3 55  6.3 NS NS
Sex, M/F 5/2 9/6 10/8 NS NS
Duration of ESLD, years 6  0.1 5  3.6 5  2.4 NS NS
Abdominal pain 1 (14.3%) 5 (31.3%) 4 (22.2%) NS NS
Abdominal distension 3 (42.9%) 7 (46.7%) 9 (50%) NS NS
Prolonged fever (>3 weeks) 5 (71.4%) 9 (56.3%) 11 (61.1%) NS NS
Underlying co-morbidities or conditions (host factors)
Diabetes mellitus 3 (42.9%) 7 (43.8%) 9 (50%) NS NS
History of antibiotics 7 (100%) 0 0 <0.001 <0.001
Variceal bleeding 2 (28.6%) 2 (12.5%) 3 (16.7%) NS NS
Hepatic encephalopathy
Grade I, II
Grade III, IV
1 (14.3%)
6 (85.7%)
6 (40%)
9 (60%)
9 (50%)
9 (50%)
NS NS
Intractable ascites 3 (42.9%) 7 (46.7%) 9 (50%) NS NS
Spontaneous bacterial peritonitis 5 (71.4%) 9 (56.3%) 11 (61.1%) NS NS
Hepatorenal syndrome 6 (85.7%) 5 (31.3%) 6 (33.3%) 0.02 0.01
Hepatocellular carcinomaa 4 (57.1%) 5 (31.3%) 6 (33.3%) NS NS
Child–Pugh score 12.9  1.3 11.8  1.9 11.9  1.9 NS NS
Child–Pugh class
Class B
Class C
0
7 (100%)
3 (18.8%)
12 (75%)
3 (16.7%)
15 (83.3%)
NS NS
MELD score 26  11.7 16.9  8.2 15  1.9 0.04 0.03
Serum biochemistry
Serum bilirubin, mg/dl 3.7  2.9 3  2.3 3.8  1.1 NS NS
Serum albumin, g/dl 1.7  0.6 2.1  0.6 2  0.6 NS NS
AST, U/l 94.7  72.4 76.8  56.8 53  34.8 NS NS
ALT, U/l 99.6  43 53  36 40  21.5 NS NS
Prothrombin time, s 22.8  4.3 20.8  5.9 19.5  4.5 NS NS
Serum creatinine, mg/dl 2.3  1.5 1.5  1.1 1.4  0.8 NS NS
WBC, 109/l 6.8  2.8 7  4.8 7.5  3.5 NS NS
Lymphocytes, % 16.6  8.1 17.9  7.2 16.4  9.2 NS NS
Neutrophils, % 70.2  4.9 68  8.2 69.5  13.4 NS NS
Monocytes, % 9.1  3.7 9.6  4.6 9.8  5.9 NS NS
Serum IL-17, pg/dl 35.4  28.8 26.8  13.7 26.3  6.6 NS NS
Hyponatremia (<130 mmol/l) 4 (57.1%) 8 (50%) 11 (61.1%) NS NS
Ascitic ﬂuid study
Protein, g/l 0.7  0.4 1.1  0.4 1.3 NS NS
Lymphocytes, %c 33  12.5 8.1  4.5 19  8.1 0.03 NS
Polymorphs (>250 cells/mm3) 3 (42.9%) 9 (52.3%) 6 (33.3%) NS NS
Cell predominant
Lymphocytes
Neutrophils
5 (71.4%)
1 (14.3%)
6 (37.5%)
6 (37.5%)
8 (44.4%)
2 (11.1%)
NS NS
Death (yes) 2 (28.6%) 0 0 0.03 0.03
ALT, alanine aminotransferase; AST, aspartate aminotransferase; ESLD, end-stage liver disease; F, female; IL-17, interleukin 17; M, male; MELD, model for end-stage liver
disease; NS, not signiﬁcant; SD, standard deviation; WBC, white blood cell count.
a Results are given as n (%), or mean  SD.
b The number includes isolated and combined bacterial infections.
c There was no statistically signiﬁcant difference with tuberculous ascites.
Table 5
Multiple regression analysis of risk factors predicting the development of fungal
infection in the study samplea.
Hazard ratio (95% CI) p-Value
Prophylactic use of antibiotics 0.6 (0.2–1.2) 0.002
MELD score 1.3 (1.01–1.6) 0.04
HRS 11.6 (1.9–71.2) 0.006
Multiple risk factors (3) 5.3 (1.9–9.3) 0.03
CI, conﬁdence interval; HRS, hepatorenal syndrome; MELD, model for end-stage
liver disease.
a Table comparison between patients with and without fungal infection
regarding risk factors.
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had a higher mortality rate than those with non-fungal infections
(p = 0.03).
3.4. Risk factor analysis for fungal infections
Multiple regression analysis was applied to determine the
factors that independently predict the development of fungal
infections, using variables that were signiﬁcantly (p < 0.05)
associated with fungal infection in the univariate analysis. A
history of prophylactic antibiotics (for spontaneous bacterial
peritonitis), hepatorenal syndrome, low ascitic ﬂuid protein
(<1 g/dl), and multiple risk factors (3) were independent risk
factors predicting fungal infection (Table 5).
4. Discussion
Our study sought to answer several questions on the frequency
of IFI in ESLD, risk factors, and cellular immunity against it. Fungalinfection is usually overlooked, with a delay in diagnosis, or passes
without being noticed. This low index of suspicion might be due to
a lack of signs of infection such as fever, or to the absence of the
classic picture of peritonitis. Sometimes, clinical presentations of
spontaneous fungal peritonitis are largely indistinguishable from
those of spontaneous bacterial peritonitis.10 In addition, the
absence of characteristic ascitic ﬂuid ﬁndings, as seen in our cases,
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transudative rather than an exudative process.11 Further factors
contributing to fungal cultures not being performed routinely are
the long period required for fungal growth and suboptimal
microscopic evaluations and culture techniques.10 Detecting
fungal DNA by PCR in serum and ascitic ﬂuid in our cases
supported the diagnostic utility and enhanced the sensitivity for
early detection of fungal infection.
The relationship between immune dysfunction and infection in
cirrhosis, known as cirrhosis-associated immune dysfunction
syndrome (CAIDS), has been investigated extensively.12 This
syndrome is a multifactorial state of dysimmunoregulation, which
is comprised of a reduction in serum bactericidal activity, opsonic
activity, and complement and ﬁbronectin levels.12 Additional
aspects of immunodeﬁciency are complicated by factors such as
malnutrition, immunosuppressive medications, and alcohol in-
take.13,14
Patients with ESLD are more susceptible to infection, where
impaired phagocytic function correlates with the severity of the
liver disease, hyperammonemia, and hyponatremia.15
Despite these qualitative and quantitative impairments in host
immunity in ESLD, the risk of fungal infection is low. Our analysis
identiﬁed IFI, i.e., the isolated type, in 15% of 46 patients with ESLD,
where four cases had a spontaneous fungal infection, two cases had
fungemia, and one had a disseminated infection. Our results are in
agreement with those of previous studies, which have shown
spontaneous fungal peritonitis associated with cirrhosis to be a
rare process, as evidenced by the small number of cases reported in
the literature.16–18
Also, this low frequency of fungal infection in cirrhotic patients
may be due to the lack of prolonged neutropenia and the presence
of adequate numbers of functional neutrophils required for normal
fungal host defense in the circulation.19,20 Chang et al.19 noted that
IFI is a well-known complication of prolonged neutropenia in
patients with hematologic malignancies undergoing treatment.
Moreover, the low frequency of fungal infection in patients with
ESLD may be attributed to accelerated tissue injury leading to rapid
death owing to activation of T cells during fungal tissue
inﬂammation.21
We determined the serum IL-17A (IL-17) level in cirrhotic
patients to explain the cellular immune system response to fungal
infection. IL-17 is one of the T cell-derived cytokines produced by
pathogen-speciﬁc Th17 CD4 T cells, speciﬁcally memory CD4+ T
cells.22 IL-17 promotes antifungal immunity by inducing the
release of a wide range of proinﬂammatory cytokines (tumor
necrosis factor (TNF), IL-1, IL-6, granulocyte colony stimulating
factor (G-CSF), and granulocyte–macrophage colony stimulating
factor (GM-CSF)), the expansion of antimicrobial factors (S100
proteins), matrix metalloproteinases (MMP1, MMP3, and MMP13),
and chemokine production (CXCL1, CXCL5, IL-8, CCL2, CCL7) at the
site of infection, and the recruitment of neutrophils.12,23 We found
that the IL-17 level was higher in our cirrhotic patients with fungal
than other groups; this may play a part in the pathophysiology as a
good immune system response against these infections resulting in
their low frequency. Furthermore, Liang et al.,24 stated that, IL-17A
may inhibit fungal growth by inducing beta-defensins and
activating the acquired immune system.
Candida and Aspergillus species were the two most frequent
pathogens in our patients. Spontaneous fungal peritonitis was
mostly attributed to Candida species, while most of the fungemia
was caused by Aspergillus species. Regarding Candida, translocation
of supercolonized fungi secondary to changes in the bacterial ﬂora
from the alimentary tract, facilitated by upper gastrointestinal
bleeding to the extraluminal areas, is the mechanism proposed for
the development of spontaneous fungal peritonitis and subsequent
further dissemination.25 Unlike Candida, Aspergillus is usuallyacquired via the respiratory tract.26 Moreover, direct percutaneous
inoculation of fungi is the proposed route of ascitic ﬂuid infection
in those patients with intractable ascites who had a history of
paracentesis.
We found no signiﬁcant differences between patients with and
without fungal infection as regards the clinical judgment, which is
in agreement with the report by Saif and Raj.10
In this study, increased ascitic ﬂuid lymphocytes were seen
among patients with fungal infections. This predominance may be
a clue to non-bacterial causes, with consideration of a possible
spontaneous fungal peritonitis.18 Also, we showed three cases of
spontaneous fungal peritonitis that had a clinical picture of
spontaneous bacterial peritonitis but with neutrocytic negative
bacterial culture ascites, supporting that this variant of spontane-
ous bacterial peritonitis is also a feature of fungal peritonitis.27
The use of prophylactic antibiotics, low ascitic ﬂuid protein
(<1 g/dl), a higher MELD score, and hepatorenal syndrome were
found to be independently associated with fungal infections in our
study patients. Moreover, patients with multiple risk factors were
more predisposed to such infections. It has been postulated that
these prophylactic antibiotics suppress or change the normal
intestinal ﬂora leading to fungal overgrowth; these organisms then
migrate across the intestinal wall to reach the peritoneal cavity and
cause fungal peritonitis and dissemination.28
Serum creatinine levels were signiﬁcantly higher in patients
with fungal infections compared to those without fungal infec-
tions. It is conceivable that renal failure (or hepatorenal syndrome)
may merely be reﬂective of the overall complicated course and
greater severity of illness, which may itself predispose these
patients to fungal infections.1 On the other hand, the association
between renal failure and fungal infections is biologically probable
where renal failure has been associated with defective cell-
mediated immunity and impaired granulocyte–macrophage func-
tion, which are the predominant host defenses against fungal
pathogens.29
We agree with Kim et al., who reported that higher MELD scores
were signiﬁcantly associated with bacterial or fungal infections,
which may contribute to a worse clinical outcome.30
In this study, no patient had a history of corticosteroid or
immunosuppressive drug therapy. Unlike other studies, none of
them had a CMV infection, which may have an impact on the risk of
fungal infection.31 This is why CMV should be investigated before
transplantation.
In addition, we noticed that the in-hospital mortality was
higher in patients with isolated fungal infections (28.6%). This is in
agreement with the study of Stiefel et al.,32 who showed a higher
mortality rate in cirrhotic patients who developed spontaneous
fungal peritonitis. Advanced hepatic cirrhosis, disseminated fungal
infection, and delayed diagnosis may contribute to these high
mortality rates. Thus, there should be an increased awareness of
fungal infection in patients with advanced cirrhosis, as delayed
diagnosis and treatment may lead to serious consequences.17,18
Also, previous studies have shown the effects of pretransplantation
fungal infections on the outcome after orthotopic liver transplan-
tation (OLT).30 Prompt OLT accompanied by adequate antifungal
therapy may be acceptable in patients with a preexisting fungal
infection unless there are overt manifestations of active infec-
tion.30
The small number of patients in this series is one of the
limitations of our study. Further studies with larger populations
are needed on fungal infections, with special attention given to
high-risk patients with ESLD.
In conclusion, the frequency of IFI in patients with ESLD was
low; however, in patients with these infections, delayed diagnosis
and treatment may contribute to high fatality rates. Hence, to
improve the outcome in these patients, clinicians should have a
E.A. Hassan et al. / International Journal of Infectious Diseases 23 (2014) 69–7474high index of suspicion for this unusual but lethal entity so that it
may be detected early, and empiric antifungal treatment should be
started, especially in high-risk patients, until appropriate treat-
ment can be used.
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conﬂicts of interest concerning this article.
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